Tel Aviv, Israel – November 12, 2014 – Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Office of Compugen, will present a corporate overview and update at the Jefferies 2014 Global Healthcare Conference in London, UK.
The Compugen presentation is scheduled to start at 10:40 a.m. GMT on Thursday, November 20, 2014. The presentation will be available online on the Investors page of the Company’s website. An archive of the event will also be available for a period of 90 days after the presentation.
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of oncology and immunology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company’s business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. Compugen’s wholly-owned U.S. subsidiary located in South San Francisco is developing monoclonal antibody therapeutic candidates against its drug targets. For additional information, please visit Compugen’s corporate website at www.cgen.com.
Global Media Liaison